A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Clinical trial NCT06824467 · RECRUITING

Trial details

NCT number: NCT06824467
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer

Start date: 2025-04-09
Primary completion: 2029-04-27
Enrollment: 770

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.